Kate Cwynarski

Thank you @AnnaSureda5 for your generosity and commitment with @TheEBMT. What a better venue to end your mandate as President of EBMT than Madrid. #EBMT26 will be in our memory for years 🙏 #hematology #bmtsm #mentoring

A dream came true.. After a vibrant second day of #ITC2022 and lots of learning, had the honor of being in the same picture with Prof @AnnaSureda5. Thank you so much for being a great role model to next-gen #WomenInMedicine, and your generosity 😊🙏

Infection-driven lymphoma: in a case in which antibiotic therapy influences the course of bronchus-associated lymphoid tissue lymphoma, this report explores the link between Tropheryma whipplei infection and lymphoma management. haematologica.org/article/view/1…

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management - PubMed pubmed.ncbi.nlm.nih.gov/41867085/?utm_…

Review @NatRevImmunol T cell lymphomas: cancers of aberrant immune synapse signalling nature.com/articles/s4157…

T cell lymphomas: cancers of aberrant immune synapse signalling dlvr.it/TRhlWm

CH affects most patients with CLL and is associated with neutropenia and RT. BAX- and U2AF1-mutated clones expand under venetoclax exposure but decline after fixed-duration treatment, indicating transient selection. Read in Blood: ow.ly/v2QU50YyBvR #CH #CLL

Delighted to present at #EBMT26 our collaborative work on behalf of @TheEBMT Lymphoma Working Party. In this large real-world study of CAR T in R/R PMBCL, outcomes favorable: ✅2y OS 75.5%, PFS 58.4% ✅2y RI 36.3%, NRM 5.3% ✅Outcomes mainly driven by disease status at infusion

Finally out in Blood Advances🎉 Our experience with Tabelecleucel in EBV+ lymphoproliferative diseases in DACH - check it out: ashpublications.org/bloodadvances/… 📷 Grateful for the collaboration 🙏 @BloodPortfolio @BloodAdvances

DLBCL Rx is changing. Rapidly. Our latest @ASHbloodjournal review reflects on the shifting landscape and what comes next. Couldn’t have asked for a better partner than Nancy Bartlett, a true labor of love. ashpublications.org/blood/article-… @CULymphoma @CUHematology

🚨Just out in @BrJHaem Hodgkin lymphoma's new era: choosing between Nivo-AVD and BrECADD We compare and contrast HD21 & SWOG1826, attempting to be as neutral and objective as possible Which would you choose? onlinelibrary.wiley.com/doi/10.1111/bj… #lymsm @mike_dickinson1

Phase 3 CLL17 trial: Fixed-duration and continuous targeted therapies are both used to treat chronic lymphocytic leukemia. Research comparing these strategies is summarized in a new Quick Take video. nejm.org/do/10.1056/NEJ…

Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage NK/T-cell lymphoma ⁦⁦@BloodAdvances⁩ Dynamic on-treatment cfEBV-DNA significantly associated with prognosis in early-stage NKTCL & may inform risk-adapted Rx ashpublications.org/bloodadvances/…

Clasification Advancement Meeting in Chicago. I was part of the Lymphoid Team! Happy and honoured to have been invited, working towards a better clasification with the aim to impact on better decisions for our patients.

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes buff.ly/iLeLZFs

🎥 @gloria_iacoboni discusses the importance of real-world evidence in shaping #CARTCell therapy care for R/R #DLBCL, highlighting its role in helping to understand the safety & efficacy of approved CAR-T products in a wider range of patients than those enrolled in clinical trials: 👉 ow.ly/O0fq50YvOvO 👈 #LYMsm #Lymphoma #ImmunoOnc #HemOnc #CART26

Original Article: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia (phase 3 RECITE trial) nejm.org/doi/full/10.10… Editorial: Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia nejm.org/doi/full/10.10… #Oncology #Gastroenterology

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study ashpublications.org/blood/article-…

Immunodeficiency-assoc PCNSL IPCG retrospective #LeonKaulen  n= 308 PLWH 21.7% post-SOT 41% AI 36.7% DLBCL EBV+ 79% Immune reconst w RM-based chemo assoc w ⬆️ RR & PFS irrespect of ID subtype +/- EBV Prognosis age > 60y KPS < 70 EBV+ @BloodPortfolio pubmed.ncbi.nlm.nih.gov/41843467/

Series 18 (Spanish) of #WiLingWednesdays is coming 🎉 🗓️ Starting May 13 💻 Free educational webinars 🧠 DLBCL, CLL, cell therapies & Hodgkin lymphoma Regional experts sharing insights on innovation, clinical practice & access in lymphoma. 📌 Don’t miss it! #womeninlymphoma